ZBTB33

Across TCGA pan-cancer cohorts, ZBTB33 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ZBTB33 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZBTB33 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZBTB33 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where ZBTB33 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.977	0.342	.002	24	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.886	.039	1	view →
CCRCC	OS	Median	All	1.000	0.806	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ZBTB33–PDAC (DFS)

Open the PDAC breakdown →